Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 6 mechanisms across 10 industry trials with a known mechanism of action.

See full pipeline →

Fibrin/Plasminogen/tPA

2 trials 1 active 1 sponsor

PCSK9 Inhibitor

1 trials 1 active 1 sponsor

Plasminogen

2 trials 2 sponsors

Acetylcholine Release Inhibitor

2 trials 1 sponsor

Integrin Receptor Antagonist

2 trials 1 sponsor

Leukocyte Growth Factor

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

204 industry-sponsored trials across 136 sponsors

View full landscape →

Showing 17 of 17 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Pharmasoft	Mexidol	—	RECRUITING	2027-04	NCT07575984
Dr. Willmar Schwabe GmbH & Co. KG	Extract of Ginkgo Biloba Leaves Tablets 240 mg (2 x 40 mg, t.i.d.)	—	RECRUITING	2027-12-31	NCT07220538
Route 92 Medical, Inc.	—	—	RECRUITING	2029-05-31	NCT07436156
Amgen	Evolocumab	PCSK9 Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-05-29	NCT05284747
SK Chemicals Co., Ltd.	Renexin CR 200/160mg	—	COMPLETED	2025-10-02	NCT05445895
Pharmasoft	Mexidol	—	COMPLETED	2023-09-12	NCT06221826
Penumbra Inc.	intravenous (IV) recombinant human tissue plasminogen activator (rtPA)	—	COMPLETED	2016-10	NCT01429350
Ipsen	Botulinum toxin type A	—	COMPLETED	2016-03	NCT02321436
Avanir Pharmaceuticals	Nuedexta (DM 20 mg/Q 10 mg)	—	COMPLETED	2015-05	NCT01799941
Jiangsu Kanion Pharmaceutical Co., Ltd	Ginkgolides Meglumine Injection	—	COMPLETED	2014-10	NCT01958957
Jiangsu Kanion Pharmaceutical Co., Ltd	Ginkgolides Meglumine Injection	—	COMPLETED	2014-06	NCT02046031
Kinetic Muscles	—	—	COMPLETED	2013-09	NCT01144715
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2013-05	NCT00924638
Sanofi	Clopidogrel	—	COMPLETED	2012-05	NCT00814268
Tibion Bionics, Inc.	—	—	COMPLETED	2011-12	NCT01499862
Stryker Neurovascular	—	—	COMPLETED	2011-08	NCT01088672
Biotronik, Inc.	Home Monitoring Guided OAC	—	TERMINATED	2013-06	NCT00559988

Showing 62 of 62 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Pharmazz, Inc.	Drug: Normal Saline	—	RECRUITING	2026-09	NCT05691244
Cytopeutics Sdn. Bhd.	Neuroncell-EX	—	RECRUITING	2026-11-30	NCT06129175
DiaMedica Therapeutics Inc	Recombinant human tissue kallikrein	—	RECRUITING	2026-12	NCT05065216
Shin Poong Pharmaceutical Co. Ltd.	SP-8203	—	RECRUITING	2027-03-30	NCT06660719
Shanghai Hutchison Pharmaceuticals Limited	SHPL-49 Injection	—	RECRUITING	2027-06-30	NCT07241520
CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.	rhTNK-tPA	—	RECRUITING	2027-09-30	NCT07201688
Boehringer Ingelheim	Tenecteplase	Fibrin/Plasminogen/tPA	RECRUITING	2027-10-02	NCT07361302
Corxel Pharmaceuticals	JX10	—	RECRUITING	2029-10-31	NCT06990867
Tatchempharmpreparaty, JSC	Dimephosphon®	—	RECRUITING	2026-01-31	NCT07167550
Johnson & Johnson	Milvexian	—	ACTIVE NOT RECRUITING	2026-11-11	NCT05702034
Supernus Pharmaceuticals, Inc.	Phase 2; Low Dose MYOBLOC	—	ACTIVE NOT RECRUITING	2023-07-01	NCT04815967
Moleac Pte Ltd.	MLC1501	—	NOT YET RECRUITING	2028-09	NCT05046106
Supergene, LLC	non-immunogenic staphylokinase	—	NOT YET RECRUITING	2028-11-01	NCT07324837
Bayer	Asundexian (BAY2433334)	—	COMPLETED	2025-10-23	NCT05686070
POLYSAN Scientific & Technological Pharmaceutical Company	Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)	—	COMPLETED	2024-06-26	NCT05935787
Shanghai Auzone Biological Technology Co., Ltd.	TTYP01 tablets	—	COMPLETED	2024-06-17	NCT06648304
Acticor Biotech	Intravenous glenzocimab (ACT017) 1000 mg	—	COMPLETED	2024-04-30	NCT05070260
Tasly Biopharmaceuticals Co., Ltd.	rhPro-UK	—	COMPLETED	2024-03-14	NCT05700591
Boehringer Ingelheim	tenecteplase	Fibrin/Plasminogen/tPA	COMPLETED	2023-10-08	NCT04915729
Qilu Pharmaceutical Co., Ltd.	Monosialoganglioside	—	COMPLETED	2023-08-30	NCT06742216
Pharmasoft	Mexidol (Ethylmethylhydroxypyridine Succinate)	—	COMPLETED	2023-08-18	NCT06437626
Angde Biotech Pharmaceutical Co., Ltd.	Injection of recombinant human tissue plasminogen kinase derivatives	—	COMPLETED	2023-06-22	NCT05295173
Materia Medica Holding	MMH-MAP	—	COMPLETED	2020-01-27	NCT03815292
Supergene, LLC	Recombinant staphylokinase	—	COMPLETED	2019-03-23	NCT03151993
AbbVie	Botulinum Toxin Type A	—	COMPLETED	2018-09-03	NCT01603615
Boehringer Ingelheim	optional ASA as comedication	—	COMPLETED	2018-08-14	NCT02239120
Merz Pharmaceuticals GmbH	NT 201	—	COMPLETED	2018-02-23	NCT02270736
Boehringer Ingelheim	alteplase	Plasminogen	COMPLETED	2017-12-11	NCT02930837
AbbVie	botulinum toxin Type A	—	COMPLETED	2017-06-29	NCT01603602
Jiangsu Simcere Pharmaceutical Co., Ltd.	Compound Edaravone Injection	—	COMPLETED	2016-12	NCT02430350
Acorda Therapeutics	dalfampridine-ER 7.5mg	—	COMPLETED	2016-09	NCT02271217
Pharmasoft	Mexidol	—	COMPLETED	2016-05-27	NCT02793687
Lanzhou Institute of Biological Products Co., Ltd	Botulinum Toxin Type A for Injection	—	COMPLETED	2016-02	NCT02280083
Pierre Fabre Medicament	F2695	—	COMPLETED	2015-02	NCT01639014
AstraZeneca	Ticagrelor 90 mg	—	COMPLETED	2014-12	NCT01225562
H. Lundbeck A/S	Desmoteplase	—	COMPLETED	2014-07	NCT00790920
Daewoong Pharmaceutical Co. LTD.	Botulinum toxin type A	—	COMPLETED	2014-05	NCT01945684
Hugel	Botulinum toxin type A(Botulax®)	—	COMPLETED	2014-05	NCT01915459
Dexa Medica Group	DLBS1033	—	COMPLETED	2013-11	NCT01790997
Daiichi Sankyo	warfarin tablets	—	COMPLETED	2013-04	NCT00781391
Boston Scientific Corporation	Warfarin	—	COMPLETED	2013-01	NCT01182441
PhotoThera, Inc	—	—	COMPLETED	2012-09	NCT01120301
GSK	GSK1358820(Botulinum toxin type A)	—	COMPLETED	2011-06	NCT01153815
Merck	Vorapaxar 2.5 mg	—	COMPLETED	2010-10-01	NCT00617123
Relox Medical, LLC	Magnesium Chloride	—	COMPLETED	2010-05	NCT00933868
Catalysis SL	Folrex	—	COMPLETED	2010-03	NCT01016119
Merck	Telcagepant	—	COMPLETED	2009-09-02	NCT00662818
Coherex Medical	—	—	TERMINATED	2023-12-21	NCT03302494
Dexa Medica Group	DLBS1033	—	TERMINATED	2023-02-21	NCT02133521
BrainsGate	—	—	TERMINATED	2018-06	NCT01874093
Bayer	Rivaroxaban (Xarelto, BAY59-7939)	—	TERMINATED	2018-02-15	NCT02313909
Roche	Alteplase	Plasminogen	TERMINATED	2017-03-22	NCT02072226
Dexa Medica Group	DLBS1033	—	TERMINATED	2017-02	NCT02362984
Acorda Therapeutics	dalfampridine-ER 7.5 mg	—	TERMINATED	2017-01	NCT02422940
AbbVie	onabotulinumtoxinA	Acetylcholine Release Inhibitor [EPC]	TERMINATED	2015-12	NCT02145676
Cerevast Therapeutics, Inc.	Standard of care tPA therapy for acute ischemic stroke	—	TERMINATED	2015-04	NCT01098981
H. Lundbeck A/S	Desmoteplase	—	TERMINATED	2014-10	NCT00856661
Codman & Shurtleff	Aspirin and Clopidogrel (Medical therapy)	—	TERMINATED	2013-04	NCT00816166
D-Pharm Ltd.	DP-b99	—	TERMINATED	2012-04	NCT00893867
Merck	Acadesine	—	TERMINATED	2010-10	NCT00872001
ZZ Biotech, LLC	3K3A-APC	—	WITHDRAWN	2026-07	NCT05484154
AbbVie	onabotulinumtoxinA	Acetylcholine Release Inhibitor [EPC]	WITHDRAWN	2017-05	NCT02145689

Showing 84 of 84 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Shanghai QuietD Biotechnology Co., Ltd.	QD202	—	RECRUITING	2026-08	NCT07581210
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS-7450 Injection	—	RECRUITING	2026-10	NCT07233070
Kunming Pharmaceuticals, Inc.	The KPCXM18 injection	—	RECRUITING	2026-10-18	NCT07279493
Changzhou Qianhong Bio-pharma Co., Ltd.	QHRD106 Injection (Low-dose group)	—	RECRUITING	2026-10-31	NCT07396337
NoNO Inc.	NoNO-42	—	RECRUITING	2026-12	NCT06403267
Shanghai Pharmaceuticals Holding Co., Ltd	LT3001 Drug:high dose	—	RECRUITING	2026-12-10	NCT05686642
ThromBio Pty. Ltd.	TBO-309: 60 mg	—	RECRUITING	2026-12-30	NCT06813651
Basking Biosciences, Inc.	BB-031	—	RECRUITING	2027-06	NCT06226805
Translational Sciences, Inc.	TS23	—	RECRUITING	2027-07	NCT05948566
Tasly Pharmaceutical Group Co., Ltd	B2065	—	RECRUITING	2027-12	NCT07371624
Takeda	TAK-755	—	RECRUITING	2027-12-06	NCT07392450
Astellas Pharma Inc	ASP2246	—	RECRUITING	2030-02-28	NCT07318714
Shaanxi Micot Pharmaceutical Technology Co., Ltd.	MT200605	—	RECRUITING	2026-05	NCT07205328
Lumosa Therapeutics Co., Ltd.	LT3001 Drug Product	—	RECRUITING	2026-03-31	NCT05198323
Shenzhen Wingor Biotechnology Co., Ltd.	hUC-MSCs treatment (high dose)	—	RECRUITING	2026-03-05	NCT07084012
Philips Portuguesa S.A.	—	—	RECRUITING	2025-08	NCT04903951
Shionogi	Redasemtide	—	ACTIVE NOT RECRUITING	2026-06-30	NCT05953480
NC Medial Research Inc	NCS-01	—	ACTIVE NOT RECRUITING	2027-10	NCT03915431
PT. Prodia Stem Cell Indonesia	Conditioned Medium	—	ACTIVE NOT RECRUITING	2026-03	NCT05008588
Anthos Therapeutics, Inc.	Abelacimab	—	ACTIVE NOT RECRUITING	2024-02-15	NCT04755283
StemCyte, Inc.	hUCB	—	NOT YET RECRUITING	2027-12	NCT06040476
Abrexa Pharmaceuticals, Inc.	J147 Emulsion for Injection	—	NOT YET RECRUITING	2028-03-01	NCT07430917
Organ, Tissue, Regeneration, Repair and Replacement	—	—	NOT YET RECRUITING	2026-03	NCT06700824
Neurodawn Pharmaceutical Co., Ltd.	RK-4 injection	—	NOT YET RECRUITING	2026-02-20	NCT07166380
Silver Creek Pharmaceuticals	scp776 (1.9 mg/kg)	—	COMPLETED	2025-09-15	NCT05585606
Moleac Pte Ltd.	MLC1501	—	COMPLETED	2025-07-18	NCT05289947
Lumosa Therapeutics Co., Ltd.	LT3001 Drug Product	—	COMPLETED	2025-05-23	NCT05403866
Shanghai Hutchison Pharmaceuticals Limited	3 ampoules of SHPL-49 Injection	—	COMPLETED	2024-11-26	NCT06202378
AbbVie	Elezanumab	—	COMPLETED	2024-04-18	NCT04309474
aptaTargets S.L.	ApTOLL	—	COMPLETED	2022-07-25	NCT04734548
Bristol-Myers Squibb	BMS-986177	—	COMPLETED	2022-03-31	NCT03766581
Bayer	BAY2433334	—	COMPLETED	2022-02-18	NCT04304508
Clinuvel Pharmaceuticals Limited	Afamelanotide	—	COMPLETED	2022-02-04	NCT04962503
Acticor Biotech	Intravenous ACT017 1000 mg	—	COMPLETED	2021-09-27	NCT03803007
Lumosa Therapeutics Co., Ltd.	LT3001 Drug Product	—	COMPLETED	2021-02-22	NCT04091945
Teijin Pharma Limited	JTR-161	—	COMPLETED	2021-02-15	NCT04608838
Shin Poong Pharmaceutical Co. Ltd.	SP-8203	—	COMPLETED	2020-10-19	NCT04479449
DiaMedica Therapeutics Inc	Recombinant human tissue kallikrein	—	COMPLETED	2020-01-23	NCT03290560
Daiichi Sankyo	DS-1040b	—	COMPLETED	2019-08-13	NCT02586233
SanBio, Inc.	SB623 Implant (2.5M)	—	COMPLETED	2018-12-05	NCT02448641
AdvanceCor GmbH	Revacept	—	COMPLETED	2018-10-05	NCT01645306
Biogen	natalizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2017-11-20	NCT02730455
Stemedica Cell Technologies, Inc.	Allogeneic adult mesenchymal bone marrow stem cells	—	COMPLETED	2017-09	NCT01297413
Shin Poong Pharmaceutical Co. Ltd.	SP-8203 High dose	—	COMPLETED	2017-05-30	NCT02787278
ZZ Biotech, LLC	3K3A-APC	—	COMPLETED	2017-04-18	NCT02222714
Genervon Biopharmaceuticals, LLC	GM602	—	COMPLETED	2016-07-07	NCT01221246
Remedy Pharmaceuticals, Inc.	Glyburide for Injection	—	COMPLETED	2016-04-04	NCT01794182
SanBio, Inc.	SB623	—	COMPLETED	2015-08	NCT01287936
Healios K.K.	MultiStem	—	COMPLETED	2015-03	NCT01436487
Biogen	natalizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2015-02	NCT01955707
Jiangsu Simcere Pharmaceutical Co., Ltd.	Compound Edaravone Injection	—	COMPLETED	2014-12	NCT01929096
Grifols Therapeutics LLC	Plasmin (Human)	—	COMPLETED	2013-11	NCT01014975
Lundbeck Japan K. K.	Desmoteplase	—	COMPLETED	2013-08	NCT01104467
Acorda Therapeutics	placebo/dalfampridine-ER	—	COMPLETED	2013-02	NCT01605825
Remedy Pharmaceuticals, Inc.	Glyburide for Injection	—	COMPLETED	2012-06-07	NCT01268683
Sygnis Bioscience GmbH & Co KG	Filgrastim	Leukocyte Growth Factor [EPC]	COMPLETED	2011-11	NCT00927836
NoNO Inc.	NA-1	—	COMPLETED	2011-04	NCT00728182
MindFrame, Inc.	—	—	COMPLETED	2011-04	NCT00810095
Tanabe Pharma Corporation	MCI-186	—	COMPLETED	2010-11	NCT00821821
Obslap Research LLC	—	—	COMPLETED	2010-09	NCT00919906
M's Science Corporation	SA4503 Low	—	COMPLETED	2009-06	NCT00639249
Orion Corporation, Orion Pharma	Levosimendan	—	COMPLETED	2009-04	NCT00698763
Moleac Pte Ltd.	Neuroaid	—	COMPLETED	2008-07	NCT00721825
ReNeuron Limited	Placebo	—	TERMINATED	2020-09-09	NCT03629275
Tanabe Pharma Corporation	Continuous infusion high-dose MCI-186	—	TERMINATED	2018-05-14	NCT03346538
Dart NeuroScience, LLC	DNS-3379	—	TERMINATED	2017-12-31	NCT03254160
Dart NeuroScience, LLC	HT-3951	—	TERMINATED	2017-12-31	NCT02530307
Roche	Basmisanil	—	TERMINATED	2017-11-03	NCT02928393
GSK	GSK249320 100/mg	—	TERMINATED	2014-07-28	NCT01808261
Pfizer	PF-03049423	—	TERMINATED	2013-12	NCT01208233
Stem Cell Therapeutics Corp.	human chorionic gonadotropin (hCG), then epoetin alfa (EPO)	—	TERMINATED	2010-04	NCT00938314
Stem Cell Therapeutics Corp.	NTx™-265: rhCG, then rEPO	—	TERMINATED	2008-10	NCT00663416
Nanjing Yoko Biomedical Co., Ltd.	Compound Edaravone Injection-Low dose	—	SUSPENDED	2026-12-31	NCT04984577
Biogen	BIIB131	—	WITHDRAWN	2025-07-07	NCT05764122
AZTherapies, Inc.	Cromolyn	—	WITHDRAWN	2024-12	NCT03202147
Techfields Inc	TF0023	—	SUSPENDED	2024-10	NCT02785120
TrueBinding, Inc.	TB006	—	WITHDRAWN	2023-12-18	NCT05156827
OsciFlex LLC	—	—	WITHDRAWN	2022-12	NCT05389488
Roche	Balovaptan	—	WITHDRAWN	2022-11-17	NCT05399550
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Pinocembrin for Injection	—	SUSPENDED	2016-12	NCT02059785
Daiichi Sankyo	SUN13837	—	WITHDRAWN	2016-05	NCT02258880
Ageless Regenerative Institute	—	—	WITHDRAWN	2014-12	NCT01453829
Stempeutics Research Pvt Ltd	Ex vivo cultured adult allogenic MSCs	—	WITHDRAWN	2013-05	NCT01091701
Stem Cell Therapeutics Corp.	NTx™-265: rhCG, then rEPO	—	WITHDRAWN	2010-06	NCT00715364

Showing 41 of 41 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Longwood Pharmaceuticals (Hangzhou) Co., Ltd.	LWP779	—	RECRUITING	2026-07-10	NCT07371455
Chendu DIAO Nine Hong Pharmaceutical Factory	DA414 Granules	—	RECRUITING	2025-09-30	NCT06525168
Algernon Pharmaceuticals	N,N-Dimethyltryptamine	—	ACTIVE NOT RECRUITING	2026-03	NCT05559931
S&Ebio Co. Ltd.	SNE-101	—	NOT YET RECRUITING	2026-03-31	NCT06995625
Jiangsu Kanion Pharmaceutical Co., Ltd	Single dose, AAPB by injection, intravenous drip.	—	NOT YET RECRUITING	2026-01-12	NCT06679998
Beijing Suncadia Pharmaceuticals Co., Ltd	HRS-4029	—	NOT YET RECRUITING	2025-10	NCT06905314
R3 Stem Cell	Amniotic and Umbilical Cord Tissue Procedure	—	NOT YET RECRUITING	2024-03-20	NCT03899298
Allife Medical Science and Technology Co., Ltd.	iEPCs	—	COMPLETED	2025-04-15	NCT05993884
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS-7450	—	COMPLETED	2025-03-18	NCT06447415
Prolong Pharmaceuticals	PP-007 (Two doses administered 24±6 hours apart) + SOC (IVT or MT or IVT+MT)	—	COMPLETED	2025-02-20	NCT04677777
Motric Bio	MTR-601	—	COMPLETED	2024-10-16	NCT06117020
Changzhou Qianhong Bio-pharma Co., Ltd.	QHRD106 Injection	—	COMPLETED	2023-11-16	NCT06380699
NoNO Inc.	NoNO-42	—	COMPLETED	2023-10-05	NCT05636306
Bayer	Asundexian (BAY2433334)	—	COMPLETED	2023-05-24	NCT05419635
Jiangsu Simcere Pharmaceutical Co., Ltd.	SIM1910-09	—	COMPLETED	2023-03-23	NCT05200728
Dr. Noah Biotech Inc.	NDC-002	—	COMPLETED	2023-03-15	NCT06090474
Changzhou Qianhong Bio-pharma Co., Ltd.	QHRD106 Injection	—	COMPLETED	2022-07-22	NCT06388772
aptaTargets S.L.	ApTOLL	—	COMPLETED	2022-06-24	NCT05569720
Lumosa Therapeutics Co., Ltd.	LT3001 drug product	—	COMPLETED	2021-08-05	NCT04809818
Moleac Pte Ltd.	MLC1501	—	COMPLETED	2020-05-16	NCT04233437
aptaTargets S.L.	ApTOLL	—	COMPLETED	2020-02-27	NCT04742062
Shin Poong Pharmaceutical Co. Ltd.	SP-8008 Prototype Capsule A	—	COMPLETED	2020-01-23	NCT04770194
Aeromics, Inc.	AER-271	—	COMPLETED	2019-07-18	NCT03804476
Gwo Xi Stem Cell Applied Technology Co., Ltd.	ADSCs	—	COMPLETED	2018-11-27	NCT02813512
NuvOx LLC	0.05 mL/kg DDFPe	—	COMPLETED	2018-07-09	NCT02963376
DiaMedica Therapeutics Inc	Recombinant human tissue kallikrein	—	COMPLETED	2017-03	NCT02868996
Bristol-Myers Squibb	BMS-986141	—	COMPLETED	2016-11	NCT02922452
Jeil Pharmaceutical Co., Ltd.	JPI-289	—	COMPLETED	2015-08	NCT02396069
Shin Poong Pharmaceutical Co. Ltd.	SP-8203	—	COMPLETED	2015-03-11	NCT01757795
Jeil Pharmaceutical Co., Ltd.	JPI-289	—	COMPLETED	2014-08	NCT01983358
Daiichi Sankyo	DS-1040b	—	COMPLETED	2014-02	NCT02071004
Rapid Medical	—	—	COMPLETED	2013-10	NCT01404403
Posit Science Corporation	—	—	COMPLETED	2013-07	NCT01641432
ReNeuron Limited	CTX0E03 neural stem cells	—	COMPLETED	2012-10	NCT01151124
H. Lundbeck A/S	Lu AA24493 (CEPO)	—	COMPLETED	2010-12	NCT00870844
Biogen	Glyburide for Injection	—	COMPLETED	2010-05-07	NCT01132703
Wyeth is now a wholly owned subsidiary of Pfizer	ILS-920	—	COMPLETED	2009-07	NCT00827190
Johnson & Johnson	CNTO 0007 or placebo (Stage A)	—	COMPLETED	—	NCT01273467
Shin Poong Pharmaceutical Co. Ltd.	SP-8356	—	TERMINATED	2021-10-28	NCT05574166
Pulse Therapeutics	—	—	TERMINATED	2014-01	NCT01519076
Suzhou Yabao Pharmaceutical R&D Co., Ltd.	SY-007/ Placebo 15mg	—	SUSPENDED	2023-12-25	NCT04891913

Novel Drugs by Company (New molecular entities)

GE HEALTHCARE 1 drug

CERETEC

TECHNETIUM TC-99M EXAMETAZIME KIT

NDA 1988

DAIICHI SANKYO INC 1 drug

SHINE 1 drug

TECHNETIUM TC-99M BICISATE KIT

NDA 1994

Reformulations (22 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.